Noxopharm Achieves Milestone in Autoimmune Drug Development with HERACLES Trial Completion

Tip Ranks
2025.09.08 01:28
portai
I'm PortAI, I can summarize articles.

Noxopharm Ltd. has successfully completed the HERACLES clinical trial for its autoimmune drug candidate SOF-SKN™, confirming its safety and tolerability at the highest dose. This milestone positions the company to explore SOF-SKN’s potential in treating autoimmune-related skin diseases. The global market for cutaneous lupus erythematosus, a target condition, is valued at over US$3.3 billion, indicating significant commercial potential for Noxopharm's innovations. Noxopharm is a clinical-stage biotech firm focused on developing novel treatments for cancer and inflammation.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Noxopharm Ltd. ( (AU:NOX) ) is now available.

Noxopharm Limited announced the successful completion of the fourth and final single-dose cohort in the HERACLES clinical trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. The trial, conducted in Australia, confirmed the safety and tolerability of SOF-SKN at its highest dose, marking a significant milestone in its development. This advancement positions Noxopharm to further explore SOF-SKN’s potential applications in treating autoimmune-related skin diseases and other conditions linked to immune system dysregulation. The global market for cutaneous lupus erythematosus, one of the target diseases, is valued at over US$3.3 billion and is expected to grow, highlighting the commercial potential of Noxopharm’s innovations.

More about Noxopharm Ltd.

Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary Sofra™ and Chroma™ technology platforms to create a pipeline of new drugs targeting inflammation, autoimmunity, mRNA drug enhancement, and oncology. Noxopharm collaborates with leading researchers to enhance its drug development capabilities.

Average Trading Volume: 297,365

Technical Sentiment Signal: Buy

Current Market Cap: A$30.68M

See more data about NOX stock on TipRanks’ Stock Analysis page.

Trending Articles:

  • Contractors Offer a Look at Things They Won’t Buy at Home Depot (NYSE:HD)
  • Airbus Stock (NASDAQ:EADSY) Slips Following Lower August Delivery Numbers
  • 3 Mega Cap Stocks with Potential to Beat the Market, 9/5/25

Disclaimer & DisclosureReport an Issue

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.